Image of doctor's back, hands holding stethoscope, with Biotricity logo faded out over the Frost & Sullivan 2018 promo stock picture to show health tech conferences.

Biotricity CEO and advisory board member to speak at major health tech conferences

November 8, 2017 | BY BIOTRICITY

REDWOOD CITY, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, today announced that CEO Waqaas Al-Siddiq and Advisory Board member Dr. David Liepert are scheduled to speak as industry thought leaders at two health technology conferences. Each speaker is recognized as an authority on how technology is poised to revolutionize healthcare, and both speaking opportunities occur as the company prepares for commercialization and expands its industry leadership.

On March 5, 2018, Biotricity CEO and Founder Waqaas Al-Siddiq will speak on an expert panel at the 23rd Annual Medical Technologies: A Frost & Sullivan Executive MindXchange. The event brings together top executives to facilitate strategic conversations in integrated healthcare and convergence, including discussions on pharmaceuticals, biotechnology, medical devices, mobile health and healthcare IT industries. The panel will focus on leveraging artificial intelligence, virtual reality, and digital assistants to enhance value. The event takes place March 4-7, 2018 at the Hilton San Diego Resort & Spa.

Dr. David Liepert, a Biotricity Advisory Board member and the Quality and Safety Leader for Calgary’s Cumming School of Medicine Department of Anesthesia, Pain and Peri-operative Medicine, is scheduled to speak on behalf of Biotricity at the University of Calgary Biomedical Engineering Sensor Technology in Monitoring Movement Workshop (STiMM) Workshop on November 16. The STiMM Workshop is focused on directing students towards the next generation of developments in Biomedical Engineering. Dr. Liepert will discuss the vital impact that medical wearables will have on the healthcare industry and outline a strategic vision for the next generation of Bioflux.

“With longer term sampling and quality data, high-fidelity medical wearables can provide us with value added information and improve and individualize patient care,” Dr. Liepert said. “Precisely measuring beat-to-beat heart rate variability and the way it changes over time, tells us about levels of function, stress, and recovery, and how it can help us predict the likelihood of diseases or complications so we can intervene both better and sooner.”

About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit or follow on Twitter: @biotricity_inc Facebook: or LinkedIn:

Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.


Media contacts

McCoin & Smith Communications Inc.

Chris McCoin

Richard Smith

Investor relations:

Biotricity Investor Relations